Sugi Predict

Sugi Predict / Compounds / 2-Picolinic Acid

2-Picolinic Acid

2-Picolinic Acid

SCHEMBL906806

O=C(O)c1ccccn1.O=Cc1ccccn1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.71
▸ L3MBTL1 Q9Y468 2/20 0.71
▸ NAPRT Q6XQN6 1/20 0.71
▸ P4HTM Q9NXG6 1/20 0.71
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ KMT2A Q03164 4/20 0.50
▸ ALDH1A1 P00352 2/20 0.48
▸ RAB9A P51151 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ ATM Q13315 1/20 0.47
▸ GSK3B P49841 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HDAC3 O15379 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL9301355 0.85 LMNA (0.83) LMNAL3MBTL1NAPRTP4HTMCES2
2-Pyridinecarboxaldehyde SCHEMBL28767990 0.85 KMT2A (0.54) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL28737810 0.84 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Pyridinecarboxaldehyde SCHEMBL27915303 0.84 MEN1 (0.64) LMNAL3MBTL1NAPRTP4HTMKMT2A
2-Picolinic Acid SCHEMBL7457912 0.84 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL29368665 0.84 — —
2-Picolinic Acid SCHEMBL674837 0.84 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL36055 0.84 — —
2-Picolinic Acid SCHEMBL2635095 0.84 L3MBTL1 (0.74) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL28492646 0.83 LMNA (0.80) LMNAL3MBTL1NAPRTP4HTMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546162-B1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORP (US) 2011-06-22 — — EP claimed
US-10745365-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2020-08-18 — — US disclosed
EP-3312292-B1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORP (US) 2019-09-25 — — EP disclosed
EP-1885875-B1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORP (US) 2019-05-22 — — EP disclosed
US-20190031629-A1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2019-01-31 — — US disclosed
US-10077244-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2018-09-18 — — US disclosed
EP-3312292-A1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS Promega Corporation (US) 2018-04-25 — — EP disclosed
EP-2778234-B1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORP (US) 2017-09-27 — — EP disclosed
US-20160176830-A1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2016-06-23 — — US disclosed
EP-2277872-B1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORP (US) 2016-03-23 — — EP disclosed
US-8476450-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2013-07-02 — — US disclosed
US-7951550-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2011-05-31 — — US disclosed
EP-2277872-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions Promega Corporation (US) 2011-01-26 — — EP disclosed
EP-2272973-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions Promega Corporation (US) 2011-01-12 — — EP disclosed
EP-2272972-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions Promega Corporation (US) 2011-01-12 — — EP disclosed
US-20080299593-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2008-12-04 — — US disclosed
EP-1935986-A2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions PROMEGA CORPORATION (US) 2008-06-25 — — EP disclosed
EP-1885875-A2 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORPORATION (US) 2008-02-13 — — EP disclosed
US-20070015790-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2007-01-18 — — US disclosed
WO-2006130551-A2 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS PROMEGA CORPORATION (US) 2006-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745365-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions GLB1, NOD1, PYCARD LMNA 279/4885L3MBTL1 394/4885NAPRT 1104/4885
US-10077244-B2 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions GLB1, NOD1, PYCARD LMNA 262/4885L3MBTL1 401/4885NAPRT 1094/4885
US-20080299593-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions GLB1, NOD1, PYCARD LMNA 279/4885L3MBTL1 394/4885NAPRT 1104/4885
US-20190031629-A1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS GLB1, NOD1, PYCARD LMNA 279/4885L3MBTL1 394/4885NAPRT 1104/4885
US-20160176830-A1 LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS GLB1, NOD1, PYCARD LMNA 262/4885L3MBTL1 401/4885NAPRT 1094/4885
US-20070015790-A1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions GLB1, NOD1, PYCARD LMNA 480/4885L3MBTL1 141/4885NAPRT 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.